U.S. growth cools while Japan battles policy runoff
- Aflac Japan sales dropped 5.6% in Q2 2026 against tough comparisons, though the first half remains up 7%.
- Japan net earned premiums are still declining, and a higher benefit ratio on new products is pressuring margins.
- Aflac U.S. lowered its full-year net earned premium growth target to just below 3% to 6%.
- The company repositioned $4.8 billion of its investment portfolio to capture higher yields.
- Aflac continues to return heavy capital, delivering $1.3 billion to shareholders in Q2 2026.
Growth slows in core markets
Aflac is facing a slower growth environment across its main segments. In Japan, new product launches like Anshin Palette and Miraito previously drove huge gains, but Q2 2026 sales fell 5.6% against those tough comparisons. More importantly, older policies continue to run off, pushing underlying earned premiums down 1.4%.
The newer Japan policies are also causing short-term margin pressure. High lapse and reissue activity on these refreshed products pushed the Q2 benefit ratio up to 64%. Management now expects the full-year ratio to hit the high end of their 60% to 63% guidance range.
In the U.S., the pivot to group benefits is working but slowing. U.S. sales grew 2.6% in Q2, but net earned premium growth of 2.3% prompted management to lower full-year growth expectations to just below their 3% to 6% target. The traditional individual business remains stagnant.
Despite operational headwinds, Aflac leans on its balance sheet. The company repositioned $4.8 billion in investments to boost yields and returned $1.3 billion to shareholders in the second quarter. Capital return remains a central pillar of the investment case.
Small policies, big back book
Aflac sells supplemental insurance. These policies help cover costs that regular health insurance may not pay, such as cash needs during cancer treatment, hospital stays, disability, or other health events.
The company makes money by collecting premiums, investing that money, and paying claims over time. Profit depends on pricing policies correctly, keeping customers, controlling expenses, and earning enough on the investment portfolio.
Japan is the larger profit engine and has high persistency. However, it also has mature policy books where premiums run off as older policies end. The U.S. business has lower persistency and relies heavily on growing group products, dental, vision, life, absence management, and disability.
Aflac also returns a large amount of cash to shareholders. It uses buybacks and dividends to support per-share value, though this financial engineering does not solve the need for actual sales growth.
What Aflac sells
Miraito cancer insurance
Miraito is Aflac Japan's newer cancer product. It drove massive sales initially but is now facing tougher year-over-year comparisons.
Anshin Palette medical insurance
Anshin Palette is the Japan medical product launched in December 2025. It helped drive early 2026 sales but is contributing to higher lapse rates.
Tsumitasu life insurance
Tsumitasu is a first sector life product in Japan. Aflac uses it to attract younger customers to cross-sell higher-margin products later.
U.S. group benefits
This includes group life, absence management, and disability. It is the primary growth engine for the U.S. segment.
U.S. individual voluntary benefits
This is Aflac's classic worksite business sold to individuals. It remains important but is currently slightly down to flat.
Dental and vision
Dental and vision are part of the U.S. platform, contributing a small but steady portion of new annualized premium sales.
Japan third-party reinsurance
Aflac Re Bermuda assumed a block of whole life annuities from Japan Post Insurance. The deal is small now but opens a new capital deployment path.
Japan and U.S. carry it
Mix uses Q1 2026 net earned premiums from the 10-Q: Aflac Japan $1.573 billion, Aflac U.S. $1.555 billion, and Corporate and other $182 million. Japan and the U.S. are the main insurance engines.
What could go wrong
Japan margin pressure from new products
High impact · High oddsNew product launches in Japan are causing increased lapse and reissue activity. This dynamic pushed the Q2 2026 benefit ratio up to 64%. Management now expects the full-year ratio to hit the high end of their 60% to 63% guidance.
U.S. growth misses targets
Medium impact · High oddsThe U.S. business is leaning heavily on group products, but overall momentum is slowing. U.S. net earned premium growth was 2.3% in Q2 2026, prompting management to lower their full-year expectation to just below the 3% to 6% target range.
Investment credit and real estate losses
Medium impact · Medium oddsAflac invests its large insurance float in bonds, loans, and other assets. The company recently repositioned $4.8 billion of its portfolio, but commercial real estate loans remain a concern. Credit losses can reduce earnings and capital flexibility.
Yen swings distort results
Medium impact · High oddsAflac earns a massive share of its business in Japan, so yen-dollar moves change reported U.S. dollar earnings. A weaker yen directly reduces the translated value of Japan profits and remittances.
In one breath
What does Aflac actually do?
Aflac sells supplemental health and life insurance in Japan and the U.S. These policies help pay costs that main health insurance may not cover.
Why is Japan so important to Aflac?
Japan is Aflac's largest profit engine and has very high policy persistency. However, it also faces challenges with mature policy books running off over time.
Is Aflac growing?
Growth is mixed. While recent new products like Miraito drove early sales spikes, Q2 2026 Japan sales fell 5.6% against those tough comparisons, and underlying earned premiums continue to decline.
Why does Aflac buy back so much stock?
Aflac generates large amounts of cash from its mature insurance books. The company uses buybacks and dividends to return this capital, delivering $1.3 billion to shareholders in Q2 2026 alone.
